metformin has been researched along with medroxyprogesterone acetate in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bagis, T; Haydardedeoglu, B; Kilicdag, EB; Simsek, E | 1 |
| Hu, Q; Ji, L; Liao, QP; Wang, YL; Xie, Y; Yu, L; Zhang, Y | 1 |
| Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M | 1 |
| Chambers, SK; Guo, D; Liao, H; Park, JY; Wang, Y; Yi, X; Zhang, D; Zhang, Z; Zheng, W; Zheng, Y | 1 |
| Niu, YJ; Shi, HR; Xie, Y | 1 |
| Chen, Y; Dong, C; Dong, M; Hou, J; Li, L; Mu, N; Qv, L; Wang, Y; Xia, M; Xue, F; Zuo, Y | 1 |
| Fujiwara, T; Hanaoka, H; Hori, M; Kawasaki, Y; Mitsuhashi, A; Shozu, M | 1 |
| Gu, W; Kobayashi, T; Mitsuhashi, A; Shozu, M | 1 |
| Hao, Y; Kuang, L; Sun, F; Zhang, B; Zhou, J | 1 |
3 trial(s) available for metformin and medroxyprogesterone acetate
| Article | Year |
|---|---|
Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cholesterol; Contraceptive Agents, Female; Drug Therapy, Combination; Female; Follow-Up Studies; Homeostasis; Homocysteine; Humans; Hypoglycemic Agents; Insulin Resistance; Medroxyprogesterone Acetate; Metformin; Polycystic Ovary Syndrome; Prospective Studies; Young Adult | 2009 |
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Fertility; Fertility Preservation; Humans; Insulin Resistance; Medroxyprogesterone Acetate; Metformin; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome; Young Adult | 2016 |
Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Topics: Adult; Antineoplastic Agents, Hormonal; Clinical Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Follow-Up Studies; Humans; Hypoglycemic Agents; Medroxyprogesterone Acetate; Metformin; Proportional Hazards Models; Prospective Studies; Single-Blind Method; Treatment Outcome | 2020 |
11 other study(ies) available for metformin and medroxyprogesterone acetate
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Medroxyprogesterone Acetate; Metformin; Models, Biological; Receptors, Progesterone; Signal Transduction; TOR Serine-Threonine Kinases | 2011 |
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Topics: 20-Hydroxysteroid Dehydrogenases; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Line; Cell Proliferation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endometrium; Female; Humans; Medroxyprogesterone Acetate; Metformin; NF-E2-Related Factor 2; Progestins; Quassins; RNA Interference; RNA, Small Interfering | 2016 |
[Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance].
Topics: Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Medroxyprogesterone Acetate; Metformin; Progestins | 2016 |
Synergistic effect of metformin and medroxyprogesterone 17‑acetate on the development of endometrial cancer.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin E; Drug Synergism; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Medroxyprogesterone Acetate; Metformin | 2018 |
Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer.
Topics: Endometrial Neoplasms; Female; Humans; Insulin-Like Growth Factor Binding Protein 1; Medroxyprogesterone Acetate; Metformin; Progestins; Prolactin; RNA, Messenger | 2022 |
MET Inhibits the Proliferation of EC Cells by Increasing MPA Sensitivity.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Metformin; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Proto-Oncogene Proteins c-akt; Receptors, Progesterone; TOR Serine-Threonine Kinases | 2023 |